Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 4/2011

01-12-2011 | Review Article

Societal Values in the Allocation of Healthcare Resources

Is it All About the Health Gain?

Authors: Dr Tania Stafinski, Devidas Menon, Deborah Marshall, Timothy Caulfield

Published in: The Patient - Patient-Centered Outcomes Research | Issue 4/2011

Login to get access

Abstract

Over the past decade, public distrust in unavoidable value-laden decisions on the allocation of resources to new health technologies has grown. In response, healthcare organizations have made considerable efforts to improve their acceptability by increasing transparency in decision-making processes. However, the social value judgments (distributive preferences of the public) embedded in them have yet to be defined. While the need to explicate such judgments has become widely recognized, the most appropriate approach to accomplishing this remains unclear. The aims of this review were to identify factors around which distributive preferences of the public have been sought, create a list of social values proposed or used in current resource allocation decision-making processes for new health technologies, and review approaches to eliciting such values from the general public. Social values proposed or used in making resource allocation decisions for new health technologies were identified through three approaches: (i) a comprehensive review of published, peer-reviewed, empirical studies of public preferences for the distribution of healthcare; (ii) an analysis of non-technical factors or social value statements considered by technology funding decision-making processes in Canada and abroad; and (iii) a review of appeals to funding decisions on grounds in part related to social value judgments. A total of 34 empirical studies, 10 technology funding decision-making processes, and 12 appeals to decisions were identified and reviewed. The key factors/patient characteristics addressed through policy statements and around which distributive preferences of the public have been sought included severity of illness, immediate need, age (and its relationship to lifetime health), health gain (amount and final outcome/health state), personal responsibility for illness, caregiving responsibilities, and number of patients who could benefit (rarity). Empirical studies typically examined the importance of these factors in isolation. Therefore, the extent to which preferences around one factor may be modified in the presence of others is still unclear. Research that seeks to clarify interactions among factors by asking the public to weigh several of them at once is needed to ensure the relevance of elicited preferences to real-world technology funding decisions
Appendix
Available only for authorised users
Literature
1.
go back to reference Pharmaceutical Management Agency (PHARMAC). How should high cost medicines be funded? Paper for public consultation. Wellington: PHARMAC, 2006 [online]. Available from URL: http://www.pharmac.govt.nz/2006/ 12/15/HCMConsult.pdf/text [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). How should high cost medicines be funded? Paper for public consultation. Wellington: PHARMAC, 2006 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​2006/​ 12/15/HCMConsult.pdf/text [Accessed 2011 Jun 10]
2.
go back to reference Department of Health and Ageing. Discussion paper 4: improved administration of commonwealth HTA processes. Canberra (ACT): Australian Government, Department of Health and Ageing, 2009 [online]. Available from URL: http://www.health.gov.au/internet/main/pub lishing.nsf/Content/9CB872326EA192E5CA25764100024 D0C/$File/discussionpaper4.pdf [Accessed 2011 Jun 10] Department of Health and Ageing. Discussion paper 4: improved administration of commonwealth HTA processes. Canberra (ACT): Australian Government, Department of Health and Ageing, 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​pub lishing.nsf/Content/9CB872326EA192E5CA25764100024 D0C/$File/discussionpaper4.pdf [Accessed 2011 Jun 10]
3.
go back to reference Department of Health and Ageing. Discussion paper 1: a conceptual framework for commonwealth HTA processes. Canberra (ACT): Australian Government, Department of Health and Ageing, 2009 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing. nsf/Content/htareview_discussion_paper1 [Accessed 2011 Jun 10] Department of Health and Ageing. Discussion paper 1: a conceptual framework for commonwealth HTA processes. Canberra (ACT): Australian Government, Department of Health and Ageing, 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​publishing.​ nsf/Content/htareview_discussion_paper1 [Accessed 2011 Jun 10]
4.
go back to reference Department of Health and Ageing. Review of health technology assessment in Australia: a discussion paper. Canberra (ACT): Australian Government, Department of Health and Ageing, 2009 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/ 208F913CD40AD7F9CA2575850080CACD/$File/htadis cussionpaper.pdf [Accessed 2011 Jun 10] Department of Health and Ageing. Review of health technology assessment in Australia: a discussion paper. Canberra (ACT): Australian Government, Department of Health and Ageing, 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​publishing.​nsf/​Content/​ 208F913CD40AD7F9CA2575850080CACD/$File/htadis cussionpaper.pdf [Accessed 2011 Jun 10]
5.
go back to reference Luft HS. Universal health care coverage: a potential hybrid solution. Obstet Gynecol Surv 2007; 62(7): 450–2CrossRef Luft HS. Universal health care coverage: a potential hybrid solution. Obstet Gynecol Surv 2007; 62(7): 450–2CrossRef
6.
go back to reference Emmelin MA, Lindholm LA, Stenlund HC, et al. Pol-ethical considerations in public health: the views of Swedish health care politicians. Eur J Public Health 1999; 9(2): 124–30CrossRef Emmelin MA, Lindholm LA, Stenlund HC, et al. Pol-ethical considerations in public health: the views of Swedish health care politicians. Eur J Public Health 1999; 9(2): 124–30CrossRef
7.
go back to reference Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ 2004; 329(7459): 227–9PubMedCrossRef Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ 2004; 329(7459): 227–9PubMedCrossRef
9.
go back to reference Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13(5): 437–52PubMedCrossRef Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13(5): 437–52PubMedCrossRef
10.
go back to reference Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329(7459): 224–7PubMedCrossRef Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329(7459): 224–7PubMedCrossRef
11.
go back to reference Commission d’etude sur les services de sante et les services sociaux. Emerging solutions: report and recommendations. Quebec City (QC): Government of Quebec, 2001 [online]. Available from URL: http://publications.msss. gouv.qc.ca/acrobat/f/documentation/2001/01-109-01a.pdf [Accessed 2011 Jun 10] Commission d’etude sur les services de sante et les services sociaux. Emerging solutions: report and recommendations. Quebec City (QC): Government of Quebec, 2001 [online]. Available from URL: http://​publications.​msss.​ gouv.qc.ca/acrobat/f/documentation/2001/01-109-01a.pdf [Accessed 2011 Jun 10]
12.
go back to reference Ekos Research Associates Inc. Evaluation of the first year of operation for the Common Drug Review: final report. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 2005 [online]. Available from URL: http://cadth.ca/media/cdr/cdr_evaluation_firstyear_ oct2005.pdf [Accessed 2011 Jun 10] Ekos Research Associates Inc. Evaluation of the first year of operation for the Common Drug Review: final report. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 2005 [online]. Available from URL: http://​cadth.​ca/​media/​cdr/​cdr_​evaluation_​firstyear_​ oct2005.pdf [Accessed 2011 Jun 10]
13.
go back to reference The health of Canadians: the federal role. Final report on the state of the health care system in Canada. Ottawa (ON): Government of Canada, Standing Senate Committee on Social Affairs, Science and Technology, 2002 [online]. Available from URL: http://www.parl.gc.ca/37/ 2/parlbus/commbus/senate/Com-e/soci-e/rep-e/repoct02v o16-e.htm [Accessed 2011 Jun 10] The health of Canadians: the federal role. Final report on the state of the health care system in Canada. Ottawa (ON): Government of Canada, Standing Senate Committee on Social Affairs, Science and Technology, 2002 [online]. Available from URL: http://​www.​parl.​gc.​ca/​37/​ 2/parlbus/commbus/senate/Com-e/soci-e/rep-e/repoct02v o16-e.htm [Accessed 2011 Jun 10]
14.
go back to reference Commission on the Future of Health Care in Canada. Building on values: the future of health care in Canada. Final report. Ottawa (ON): Government of Canada, 2002 [online]. Available from URL: http://www.collectionsca nada.gc.ca/webarchives/20071122004429/http://www.hc-sc. gc.ca/english/pdf/romanow/pdfs/hcc_final_report.pdf [Accessed 2011 Jun 10 Commission on the Future of Health Care in Canada. Building on values: the future of health care in Canada. Final report. Ottawa (ON): Government of Canada, 2002 [online]. Available from URL: http://​www.​collectionsca nada.gc.ca/webarchives/20071122004429/http://www.hc-sc. gc.ca/english/pdf/romanow/pdfs/hcc_final_report.pdf [Accessed 2011 Jun 10
15.
go back to reference Dault M, Lomas J, Barer M. Listening for direction II: a national consultation on health services and policy issues for 2004–2007. Final report. Ottawa (ON): Canadian Health Services Research Foundation, 2004 [online]. Available from URL: http://www.cihr-irsc.gc.ca/e/24509.html [Accessed 2011 Jun 10] Dault M, Lomas J, Barer M. Listening for direction II: a national consultation on health services and policy issues for 2004–2007. Final report. Ottawa (ON): Canadian Health Services Research Foundation, 2004 [online]. Available from URL: http://​www.​cihr-irsc.​gc.​ca/​e/​24509.​html [Accessed 2011 Jun 10]
16.
go back to reference Martin DK, Giacomini M, Singer PA. Fairness, accountability for reasonableness, and the views of priority setting decision-makers. Health Policy 2002; 61(3): 279–90PubMedCrossRef Martin DK, Giacomini M, Singer PA. Fairness, accountability for reasonableness, and the views of priority setting decision-makers. Health Policy 2002; 61(3): 279–90PubMedCrossRef
17.
go back to reference Dolan P, Edlin R, Tsuchiya A, et al. It ain’t what you do, it’s the way that you do it: characteristics of procedural justice and their importance in social decision-making. J Econ Behav Organ 2007; 64(1): 157–70CrossRef Dolan P, Edlin R, Tsuchiya A, et al. It ain’t what you do, it’s the way that you do it: characteristics of procedural justice and their importance in social decision-making. J Econ Behav Organ 2007; 64(1): 157–70CrossRef
18.
go back to reference Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff 1997; 26(4): 303–50PubMedCrossRef Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff 1997; 26(4): 303–50PubMedCrossRef
19.
go back to reference Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff (Millwood) 1998; 17(5): 50–64CrossRef Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff (Millwood) 1998; 17(5): 50–64CrossRef
21.
go back to reference Stafinski T, Menon D, Philippon D, et al. Health technology funding decision making processes around the world: the same yet different. Pharmacoeconomics 2011; 29(6): 475–95PubMedCrossRef Stafinski T, Menon D, Philippon D, et al. Health technology funding decision making processes around the world: the same yet different. Pharmacoeconomics 2011; 29(6): 475–95PubMedCrossRef
22.
go back to reference National Institute for Health and Clinical Excellence. First report of session 2007–08. Volume 1. Report, together with formal minutes. London: House of Commons, Health Committee, 2008 [online]. Available from URL: http://www.publications.parliament.uk/pa/cm200708/cmselect/ cmhealth/27/27.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. First report of session 2007–08. Volume 1. Report, together with formal minutes. London: House of Commons, Health Committee, 2008 [online]. Available from URL: http://​www.​publications.​parliament.​uk/​pa/​cm200708/​cmselect/​ cmhealth/27/27.pdf [Accessed 2011 Jun 10]
23.
go back to reference Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect 2002; 5(3): 210–22PubMedCrossRef Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect 2002; 5(3): 210–22PubMedCrossRef
24.
go back to reference Hansen P. A theoretical review of PHARMAC’s overarching approach to deciding which pharmaceuticals to fund, including high cost ones. Wellington: Pharmaceutical Management Agency (PHARMAC), 2006 [online]. Available from URL: http://www.pharmac.govt.nz/2006/ 06/06/HCM2.pdf[Accessed 2011 Jun 10] Hansen P. A theoretical review of PHARMAC’s overarching approach to deciding which pharmaceuticals to fund, including high cost ones. Wellington: Pharmaceutical Management Agency (PHARMAC), 2006 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​2006/​ 06/06/HCM2.pdf[Accessed 2011 Jun 10]
25.
go back to reference Childress J. Who shall live when not all can live? In: Gorovitz S, editor. Moral problems in medicine. 2nd ed. Englewood Cliffs (NJ): Prentice Hall, 1983: 640-9 Childress J. Who shall live when not all can live? In: Gorovitz S, editor. Moral problems in medicine. 2nd ed. Englewood Cliffs (NJ): Prentice Hall, 1983: 640-9
26.
go back to reference Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics 2008; 34(7): 540–4PubMedCrossRef Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics 2008; 34(7): 540–4PubMedCrossRef
27.
go back to reference Brock DW. Priority to the worse off in health-care resource prioritization. In: Rhodes R, Battin MP, Silvers A, editors. Medicine and social justice: essays on the distribution of health care. Oxford: Oxford University Press, 2002: 362–72 Brock DW. Priority to the worse off in health-care resource prioritization. In: Rhodes R, Battin MP, Silvers A, editors. Medicine and social justice: essays on the distribution of health care. Oxford: Oxford University Press, 2002: 362–72
28.
go back to reference Cookson R, Dolan P. Public views on health care rationing: a group discussion study. Health Policy 1999; 49(1-2): 63–74PubMedCrossRef Cookson R, Dolan P. Public views on health care rationing: a group discussion study. Health Policy 1999; 49(1-2): 63–74PubMedCrossRef
29.
go back to reference Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997; 6(2): 117–32PubMedCrossRef Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997; 6(2): 117–32PubMedCrossRef
30.
go back to reference Le Grand J. Equity and choice: an essay in economics and applied philosophy. London: Harper-Collins, 1991 Le Grand J. Equity and choice: an essay in economics and applied philosophy. London: Harper-Collins, 1991
31.
go back to reference Harris J. Maximising the health of the whole community: the principal objective of the NHS ought to be to maximise the aggregate improvement in the health status of the whole community. The case against (what the principal objective of the NHS should really be). In: New B, editor. Rationing: talk and action in health care. London: King’s Fund, BMJ Publishing Group, 1997: 100–6 Harris J. Maximising the health of the whole community: the principal objective of the NHS ought to be to maximise the aggregate improvement in the health status of the whole community. The case against (what the principal objective of the NHS should really be). In: New B, editor. Rationing: talk and action in health care. London: King’s Fund, BMJ Publishing Group, 1997: 100–6
32.
go back to reference Culyer T. Maximising the health of the whole community: the principal objective of the NHS ought to be to maximise the aggregate improvement in the health status of the whole community. The case for. In: New B, editor. Rationing: talk and action in health care. London: King’s Fund, BMJ Publishing Group, 1997: 95–100 Culyer T. Maximising the health of the whole community: the principal objective of the NHS ought to be to maximise the aggregate improvement in the health status of the whole community. The case for. In: New B, editor. Rationing: talk and action in health care. London: King’s Fund, BMJ Publishing Group, 1997: 95–100
33.
go back to reference Bates MJ. Tactics and vocabularies in online searching. In: White HD, Bates MJ, Wilson P, editors. For information specialists: interpretations of reference and bibliographic work. Norwood (NJ): Ablex Publishing, 1992 Bates MJ. Tactics and vocabularies in online searching. In: White HD, Bates MJ, Wilson P, editors. For information specialists: interpretations of reference and bibliographic work. Norwood (NJ): Ablex Publishing, 1992
34.
go back to reference Cooper H, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage Foundation, 1994 Cooper H, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage Foundation, 1994
35.
go back to reference Cochrane handbook for systematic reviews of interventions. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Oxford: The Cochrane Collaboration, 2008 Cochrane handbook for systematic reviews of interventions. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Oxford: The Cochrane Collaboration, 2008
36.
go back to reference Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20(1): 37–46CrossRef Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20(1): 37–46CrossRef
37.
go back to reference Noyes J, Popay J, Pearson A, et al. Qualitative research and Cochrane reviews. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Oxford: The Cochrane Collaboration, 2008 Noyes J, Popay J, Pearson A, et al. Qualitative research and Cochrane reviews. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Oxford: The Cochrane Collaboration, 2008
38.
go back to reference List of countries by GDP (nominal) per capita. In: Wikipedia, the free encyclopedia. San Francisco (CA): Wikipedia Foundation, Inc., 2010 [online]. Available from URL: http://en.wikipedia.org/wiki/list_of_countries_by_ GDP_(nominal)_per_capita [Accessed 2010 Jul 10] List of countries by GDP (nominal) per capita. In: Wikipedia, the free encyclopedia. San Francisco (CA): Wikipedia Foundation, Inc., 2010 [online]. Available from URL: http://​en.​wikipedia.​org/​wiki/​list_​of_​countries_​by_​ GDP_(nominal)_per_capita [Accessed 2010 Jul 10]
39.
go back to reference Mays N, Pope C. Quality in qualitative health research. In: Pope C, Mays N, editors. Qualitative research in health care. 3rd ed. London: Blackwell Publishing/BMJ Books, 2006: 82–101 Mays N, Pope C. Quality in qualitative health research. In: Pope C, Mays N, editors. Qualitative research in health care. 3rd ed. London: Blackwell Publishing/BMJ Books, 2006: 82–101
40.
go back to reference Crabtree BF, Miller WL, editors. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications, 1999 Crabtree BF, Miller WL, editors. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications, 1999
41.
go back to reference Roberts T, Bryan S, Heginbotham C, et al. Public involvement in health care priority setting: an economic perspective. Health Expect 1999; 2(4): 235–44PubMedCrossRef Roberts T, Bryan S, Heginbotham C, et al. Public involvement in health care priority setting: an economic perspective. Health Expect 1999; 2(4): 235–44PubMedCrossRef
42.
go back to reference Dolan P. Effect of age on health state valuations. J Health Services Res Policy 2000; 5(1): 17–21 Dolan P. Effect of age on health state valuations. J Health Services Res Policy 2000; 5(1): 17–21
43.
go back to reference Green C. Investigating public preferences on ‘severity of health’ as a relevant condition for setting healthcare priorities. Soc Sci Med 2009; 68(12): 2247–55PubMedCrossRef Green C. Investigating public preferences on ‘severity of health’ as a relevant condition for setting healthcare priorities. Soc Sci Med 2009; 68(12): 2247–55PubMedCrossRef
44.
go back to reference Baker AD, Bassran A, Paterson-Brown S. Opinions of patients and the public regarding NHS priorities. Scott Med J 2001; 46(5): 140–2PubMed Baker AD, Bassran A, Paterson-Brown S. Opinions of patients and the public regarding NHS priorities. Scott Med J 2001; 46(5): 140–2PubMed
45.
go back to reference Dolan P, Tsuchiya A. The person trade-off method and the transitivity principle: an example from preferences over age weighting. Health Econ 2003; 12(6): 505–10PubMedCrossRef Dolan P, Tsuchiya A. The person trade-off method and the transitivity principle: an example from preferences over age weighting. Health Econ 2003; 12(6): 505–10PubMedCrossRef
46.
go back to reference Gyrd-Hansen D. Investigating the social value of health changes. J Health Econ 2004; 23(6): 1101–16PubMedCrossRef Gyrd-Hansen D. Investigating the social value of health changes. J Health Econ 2004; 23(6): 1101–16PubMedCrossRef
47.
go back to reference Chan HM, Cheung GM, Yip AK. Selection criteria for recipients of scarce donor livers: a public opinion survey in Hong Kong. Hong Kong Med J 2006; 12(1): 40–6PubMed Chan HM, Cheung GM, Yip AK. Selection criteria for recipients of scarce donor livers: a public opinion survey in Hong Kong. Hong Kong Med J 2006; 12(1): 40–6PubMed
48.
go back to reference Werner P. Israeli lay persons’ views on priority-setting criteria for Alzheimer’s disease. Health Expect 2009; 12(2): 187–96PubMed Werner P. Israeli lay persons’ views on priority-setting criteria for Alzheimer’s disease. Health Expect 2009; 12(2): 187–96PubMed
49.
go back to reference Bleichrodt H, Pinto Prades JL. New evidence of preference reversals in health utility measurement. Health Econ 2009; 18(6): 713–26PubMedCrossRef Bleichrodt H, Pinto Prades JL. New evidence of preference reversals in health utility measurement. Health Econ 2009; 18(6): 713–26PubMedCrossRef
50.
go back to reference Green C, Gerard K. Exploring the social value of healthcare interventions: a stated preference discrete choice experiment. Health Econ 2009; 18(8): 951–76PubMedCrossRef Green C, Gerard K. Exploring the social value of healthcare interventions: a stated preference discrete choice experiment. Health Econ 2009; 18(8): 951–76PubMedCrossRef
51.
go back to reference Friedman SM, Schofield L, Tirkos S. Do as I say, not as I do: a survey of public impressions of queue-jumping and preferential access. Eur J Emerg Med 2007; 14(5): 260–4PubMedCrossRef Friedman SM, Schofield L, Tirkos S. Do as I say, not as I do: a survey of public impressions of queue-jumping and preferential access. Eur J Emerg Med 2007; 14(5): 260–4PubMedCrossRef
52.
go back to reference Mossialos E, King D. Citizens and rationing: analysis of a European survey. Health Policy 1999; 49(1-2): 75–135PubMedCrossRef Mossialos E, King D. Citizens and rationing: analysis of a European survey. Health Policy 1999; 49(1-2): 75–135PubMedCrossRef
53.
go back to reference Ubel PA, Richardson J, Prades JL. Life-saving treatments and disabilities: are all QALYs created equal? Int J Technol Assess Health Care 1999; 15(4): 738–48PubMed Ubel PA, Richardson J, Prades JL. Life-saving treatments and disabilities: are all QALYs created equal? Int J Technol Assess Health Care 1999; 15(4): 738–48PubMed
54.
go back to reference Ubel PA. How stable are people’s preferences for giving priority to severely ill patients? Soc Sci Med 1999; 49(7): 895–903PubMedCrossRef Ubel PA. How stable are people’s preferences for giving priority to severely ill patients? Soc Sci Med 1999; 49(7): 895–903PubMedCrossRef
55.
go back to reference Anand P, Wailoo A. Utilities versus rights to publicly provided goods: arguments and evidence from health care rationing. Economica 2000; 67(268): 543–77CrossRef Anand P, Wailoo A. Utilities versus rights to publicly provided goods: arguments and evidence from health care rationing. Economica 2000; 67(268): 543–77CrossRef
56.
go back to reference Ubel PA, Baron J, Nash B, et al. Are preferences for equity over efficiency in health care allocation “all or nothing”? Med Care 2000; 38(4): 366–73PubMedCrossRef Ubel PA, Baron J, Nash B, et al. Are preferences for equity over efficiency in health care allocation “all or nothing”? Med Care 2000; 38(4): 366–73PubMedCrossRef
57.
go back to reference Ubel PA, Jepson C, Baron J, et al. Allocation of transplantable organs: do people want to punish patients for causing their illness? Liver Transpl 2001; 7(7): 600–7PubMedCrossRef Ubel PA, Jepson C, Baron J, et al. Allocation of transplantable organs: do people want to punish patients for causing their illness? Liver Transpl 2001; 7(7): 600–7PubMedCrossRef
58.
go back to reference Ubel PA, Baron J, Asch DA. Preference for equity as a framing effect. Med Decis Making 2001; 21(3): 180–9PubMed Ubel PA, Baron J, Asch DA. Preference for equity as a framing effect. Med Decis Making 2001; 21(3): 180–9PubMed
59.
go back to reference Fortes PA, Zoboli EL. A study on the ethics of micro-allocation of scarce resources in health care. J Med Ethics 2002; 28(4): 266–9PubMedCrossRef Fortes PA, Zoboli EL. A study on the ethics of micro-allocation of scarce resources in health care. J Med Ethics 2002; 28(4): 266–9PubMedCrossRef
60.
go back to reference Beach MC, Asch DA, Jepson C, et al. Public response to cost-quality tradeoffs in clinical decisions. Med Decis Making 2003; 23(5): 369–78PubMedCrossRef Beach MC, Asch DA, Jepson C, et al. Public response to cost-quality tradeoffs in clinical decisions. Med Decis Making 2003; 23(5): 369–78PubMedCrossRef
61.
go back to reference Edwards RT, Boland A, Wilkinson C, et al. Clinical and lay preferences for the explicit prioritisation of elective waiting lists: survey evidence from Wales. Health Policy 2003; 63(3): 229–37PubMedCrossRef Edwards RT, Boland A, Wilkinson C, et al. Clinical and lay preferences for the explicit prioritisation of elective waiting lists: survey evidence from Wales. Health Policy 2003; 63(3): 229–37PubMedCrossRef
62.
go back to reference Tsuchiya A, Dolan P. Do NHS clinicians and members of the public share the same views about reducing inequalities in health? Soc Sci Med 2007; 64(12): 2499–503PubMedCrossRef Tsuchiya A, Dolan P. Do NHS clinicians and members of the public share the same views about reducing inequalities in health? Soc Sci Med 2007; 64(12): 2499–503PubMedCrossRef
63.
go back to reference Kasemsup V, Schommer JC, Cline RR, et al. Citizen’s preferences regarding principles to guide health-care al-location decisions in Thailand. Value Health 2008; 11(7): 1194–202PubMedCrossRef Kasemsup V, Schommer JC, Cline RR, et al. Citizen’s preferences regarding principles to guide health-care al-location decisions in Thailand. Value Health 2008; 11(7): 1194–202PubMedCrossRef
64.
go back to reference Dolan P, Shaw R. A note on a discussion group study of public preferences regarding priorities in the allocation of donor kidneys. Health Policy 2004; 68(1): 31–6PubMedCrossRef Dolan P, Shaw R. A note on a discussion group study of public preferences regarding priorities in the allocation of donor kidneys. Health Policy 2004; 68(1): 31–6PubMedCrossRef
65.
go back to reference Tsuchiya A, Dolan P. Equality of what in health? Distinguishing between outcome egalitarianism and gain egalitarianism. Health Econ 2009; 18(2): 147–59PubMedCrossRef Tsuchiya A, Dolan P. Equality of what in health? Distinguishing between outcome egalitarianism and gain egalitarianism. Health Econ 2009; 18(2): 147–59PubMedCrossRef
66.
go back to reference Lenaghan J. Involving the public in rationing decisions: the experience of citizens juries. Health Policy 1999; 49(1–2): 45–61PubMedCrossRef Lenaghan J. Involving the public in rationing decisions: the experience of citizens juries. Health Policy 1999; 49(1–2): 45–61PubMedCrossRef
67.
go back to reference Dolan P, Cookson R. A qualitative study of the extent to which health gain matters when choosing between groups of patients. Health Policy 2000; 51(1): 19–30PubMedCrossRef Dolan P, Cookson R. A qualitative study of the extent to which health gain matters when choosing between groups of patients. Health Policy 2000; 51(1): 19–30PubMedCrossRef
68.
go back to reference Costa-Font J, Rovira J. Eliciting preferences for collectively financed health programmes: the ‘willingness to assign’ approach. Appl Econ 2005; 37(14): 1571–83CrossRef Costa-Font J, Rovira J. Eliciting preferences for collectively financed health programmes: the ‘willingness to assign’ approach. Appl Econ 2005; 37(14): 1571–83CrossRef
69.
go back to reference Guttman N, Shalev C, Kaplan G, et al. What should be given a priority: costly medications for relatively few people or inexpensive ones for many? The Health Parliament public consultation initiative in Israel. Health Expect 2008; 11(2): 177–88PubMedCrossRef Guttman N, Shalev C, Kaplan G, et al. What should be given a priority: costly medications for relatively few people or inexpensive ones for many? The Health Parliament public consultation initiative in Israel. Health Expect 2008; 11(2): 177–88PubMedCrossRef
70.
go back to reference Dolan P, Tsuchiya A. Health priorities and public preferences: the relative importance of past health experience and future health prospects. J Health Econ 2005; 24(4): 703–14PubMedCrossRef Dolan P, Tsuchiya A. Health priorities and public preferences: the relative importance of past health experience and future health prospects. J Health Econ 2005; 24(4): 703–14PubMedCrossRef
71.
go back to reference PBAC submission to the review of health technology assessment in Australia. Canberra (ACT): Pharmaceutical Benefits Advisory Committee, 2009 PBAC submission to the review of health technology assessment in Australia. Canberra (ACT): Pharmaceutical Benefits Advisory Committee, 2009
72.
go back to reference International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map. Australia: health policy decision process. Lawrenceville (NJ): ISPOR, 2009 [online]. Available from URL: http://www.ispor.org/HTARoadMaps/AustraliaHP.asp [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map. Australia: health policy decision process. Lawrenceville (NJ): ISPOR, 2009 [online]. Available from URL: http://​www.​ispor.​org/​HTARoadMaps/​AustraliaHP.​asp [Accessed 2011 Jun 10]
73.
go back to reference Medical devices regulations basics. Canberra (ACT): Australian Government, Department of Health and Ageing, Therapeutic Goods Administration, 2011 [online]. Available from URL: http://www.tga.gov.au/industry/devices-basics.htm [Accessed 2011 Jun 10] Medical devices regulations basics. Canberra (ACT): Australian Government, Department of Health and Ageing, Therapeutic Goods Administration, 2011 [online]. Available from URL: http://​www.​tga.​gov.​au/​industry/​devices-basics.​htm [Accessed 2011 Jun 10]
74.
go back to reference How therapeutic goods are regulated in Australia. Canberra (ACT): Australian Government, Department of Health and Ageing, Therapeutic Goods Administration, 2011 [online]. Available from URL: http://www.tga.gov.au/industry/ basics-regulation.htm [Accessed 2011 Jun 10] How therapeutic goods are regulated in Australia. Canberra (ACT): Australian Government, Department of Health and Ageing, Therapeutic Goods Administration, 2011 [online]. Available from URL: http://​www.​tga.​gov.​au/​industry/​ basics-regulation.htm [Accessed 2011 Jun 10]
75.
go back to reference Morgan SG, McMahon M, Mitton C, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff 2006; 25(2): 337–47CrossRef Morgan SG, McMahon M, Mitton C, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff 2006; 25(2): 337–47CrossRef
76.
go back to reference Healy J, Sharman E, Lokuge B. Australia: health system review [Health Systems in Transition]. Copenhagen: European Observatory on Health Care Systems, WHO Regional Office for Europe, 2006 [online]. Available from URL: http://www.euro.who.int/__data/assets/pdf_file/0007/ 96433/E89731.pdf [Accessed 2011 Jun 10] Healy J, Sharman E, Lokuge B. Australia: health system review [Health Systems in Transition]. Copenhagen: European Observatory on Health Care Systems, WHO Regional Office for Europe, 2006 [online]. Available from URL: http://​www.​euro.​who.​int/​_​_​data/​assets/​pdf_​file/​0007/​ 96433/E89731.pdf [Accessed 2011 Jun 10]
77.
go back to reference Haas M, Viney R, Gallego G. Implementing guidelines for reimbursement in Australia: how the PBAC & MSAC use comparative cost-effectiveness. Sydney (NSW): Centre for Health Economics (CHERE)/University of Technology Sydney, 2006 [online]. Available from URL: http://www.hpm.org/Downloads/Symposium_Krakau/Marion_ Haas_Australia.pdf [Accessed 2010 Jan 7] Haas M, Viney R, Gallego G. Implementing guidelines for reimbursement in Australia: how the PBAC & MSAC use comparative cost-effectiveness. Sydney (NSW): Centre for Health Economics (CHERE)/University of Technology Sydney, 2006 [online]. Available from URL: http://​www.​hpm.​org/​Downloads/​Symposium_​Krakau/​Marion_​ Haas_Australia.pdf [Accessed 2010 Jan 7]
78.
go back to reference International Society for Pharmacoeconomics and Out-comes Research. Pharmacoeconomic guidelines around the world: Australia. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://www.ispor.org/PE guidelines/countrydet.asp?c=1&t=2 [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Out-comes Research. Pharmacoeconomic guidelines around the world: Australia. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://​www.​ispor.​org/​PE guidelines/countrydet.asp?c=1&t=2 [Accessed 2011 Jun 10]
79.
go back to reference PBAC outcomes by meeting. Recommendations made by the PBAC: March 2010. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2010 [online]. Available from URL: http://www.health.gov.au/ internet/main/publishing.nsf/Content/pbacrec-mar10 [Accessed 2011 Jun 10] PBAC outcomes by meeting. Recommendations made by the PBAC: March 2010. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2010 [online]. Available from URL: http://​www.​health.​gov.​au/​ internet/main/publishing.nsf/Content/pbacrec-mar10 [Accessed 2011 Jun 10]
80.
go back to reference Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) — December 2008, version 4.3. Canberra (ACT): Australian Government, Department of Health and Ageing, 2008 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/ pbacguidelines-index [Accessed 2011 Jun 10] Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) — December 2008, version 4.3. Canberra (ACT): Australian Government, Department of Health and Ageing, 2008 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​publishing.​nsf/​Content/​ pbacguidelines-index [Accessed 2011 Jun 10]
81.
go back to reference Department of Health and Ageing. Alternative arrangements for medicines: other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS). Canberra (ACT): Government of Australia, Department of Health and Ageing, 2010 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/content/ lsdp-info [Accessed 2011 Jun 1 Department of Health and Ageing. Alternative arrangements for medicines: other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS). Canberra (ACT): Government of Australia, Department of Health and Ageing, 2010 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​publishing.​nsf/​content/​ lsdp-info [Accessed 2011 Jun 1
82.
go back to reference Department of Health and Ageing. The review of the life saving drugs program. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2010 [online]. Available from URL: http://www.health.gov.au/in ternet/main/publishing.nsf/Content/lsdp-info/$File/LSD Preview.pdf [Accessed 2011 Jun 10] Department of Health and Ageing. The review of the life saving drugs program. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2010 [online]. Available from URL: http://​www.​health.​gov.​au/​in ternet/main/publishing.nsf/Content/lsdp-info/$File/LSD Preview.pdf [Accessed 2011 Jun 10]
83.
go back to reference Department of Health and Ageing. About the PBS: how do drugs get on the scheme? Canberra (ACT): Government of Australia, Pharmaceutical Benefits Scheme (PBS), 2006 [online]. Available from URL: http://www.health.gov.au/ internet/main/publishing.nsf/Content/health-pbs-general-pbs-phbenbir.htm [Accessed 2011 Jun Department of Health and Ageing. About the PBS: how do drugs get on the scheme? Canberra (ACT): Government of Australia, Pharmaceutical Benefits Scheme (PBS), 2006 [online]. Available from URL: http://​www.​health.​gov.​au/​ internet/main/publishing.nsf/Content/health-pbs-general-pbs-phbenbir.htm [Accessed 2011 Jun
84.
go back to reference Department of Health and Ageing. Updated (22 April 2005) questions and answers on new pricing and listing arrangements for generic medicines on the Pharmaceutical Benefits Scheme (PBS). Canberra (ACT): Government of Australia, Pharmaceutical Benefits Scheme (PBS), 2005 [online]. Available from URL: http://www.health.gov.au/ internet/main/publishing.nsf/Content/C96C6E1108952858 CA25732B0048D611/$File/qa22april.pdf [Accessed 2011 Jun 10] Department of Health and Ageing. Updated (22 April 2005) questions and answers on new pricing and listing arrangements for generic medicines on the Pharmaceutical Benefits Scheme (PBS). Canberra (ACT): Government of Australia, Pharmaceutical Benefits Scheme (PBS), 2005 [online]. Available from URL: http://​www.​health.​gov.​au/​ internet/main/publishing.nsf/Content/C96C6E1108952858 CA25732B0048D611/$File/qa22april.pdf [Accessed 2011 Jun 10]
85.
go back to reference Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS): continuation rules for PBS-listed drugs. Canberra (ACT): Government of Australia, Pharmaceutical Benefits Scheme (PBS), 2005 [online]. Available from URL: http://www.health.gov.au/internet/main/pub lishing.nsf/Content/health-pbs-general-continuation_rules. htm [Accessed 2011 Jun 10] Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS): continuation rules for PBS-listed drugs. Canberra (ACT): Government of Australia, Pharmaceutical Benefits Scheme (PBS), 2005 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​pub lishing.nsf/Content/health-pbs-general-continuation_rules. htm [Accessed 2011 Jun 10]
86.
go back to reference Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS): the impact of PBS reform. Report to the Parliament. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2010 [online]. Available from URL: http://www.health.gov.au/internet/main/pub lishing.nsf/Content/pbs-reform-report [Accessed 2011 Jun 10] Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS): the impact of PBS reform. Report to the Parliament. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2010 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​pub lishing.nsf/Content/pbs-reform-report [Accessed 2011 Jun 10]
87.
go back to reference Department of Health and Ageing. Advisory Committee on Prescription Medicines (ACPM). Canberra (ACT): Government of Australia, Department of Health and Ageing. Therapeutic Goods Administration, 2011 [online]. Available from URL: http://www.tga.gov.au/about/ committees-acpm.htm [Accessed 2011 Jun 10] Department of Health and Ageing. Advisory Committee on Prescription Medicines (ACPM). Canberra (ACT): Government of Australia, Department of Health and Ageing. Therapeutic Goods Administration, 2011 [online]. Available from URL: http://​www.​tga.​gov.​au/​about/​ committees-acpm.htm [Accessed 2011 Jun 10]
88.
go back to reference Department of Health and Ageing. Current MSAC membership. Canberra (ACT): Medical Services Advisory Committee (MSAC), 2010 [online]. Available from URL: http://www.msac.gov.au/internet/msac/publishing.nsf/con tent/current-membership-1 [Accessed 2011 Jun 10] Department of Health and Ageing. Current MSAC membership. Canberra (ACT): Medical Services Advisory Committee (MSAC), 2010 [online]. Available from URL: http://​www.​msac.​gov.​au/​internet/​msac/​publishing.​nsf/​con tent/current-membership-1 [Accessed 2011 Jun 10]
89.
go back to reference Department of Health and Ageing. Part 1: roles and responsibilities of the PBAC. In: 1995 guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee including major submissions involving economic analysis. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2010 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Con tent/health-pbs-general-pubs-guidelines-part1.htm#role [Accessed 2011 Jun 10] Department of Health and Ageing. Part 1: roles and responsibilities of the PBAC. In: 1995 guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee including major submissions involving economic analysis. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2010 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​publishing.​nsf/​Con tent/health-pbs-general-pubs-guidelines-part1.htm#role [Accessed 2011 Jun 10]
90.
go back to reference Department of Health and Ageing. Pharmaceutical Benefits Advisory Committee (PBAC) membership. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2009 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/ health-pbs-general-listing-committee3.htm [Accessed 2011 Jun 10] Department of Health and Ageing. Pharmaceutical Benefits Advisory Committee (PBAC) membership. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​publishing.​nsf/​Content/​ health-pbs-general-listing-committee3.htm [Accessed 2011 Jun 10]
91.
go back to reference Department of Health and Ageing. PBAC outcomes explained. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2005 [online]. Available from URL: http://www.health.gov.au/internet/main/pub lishing.nsf/Content/health-pbs-general-outcomes.htm [Accessed 2011 Jun 10] Department of Health and Ageing. PBAC outcomes explained. Canberra (ACT): Government of Australia, Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee (PBAC), 2005 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​pub lishing.nsf/Content/health-pbs-general-outcomes.htm [Accessed 2011 Jun 10]
92.
go back to reference Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009; 87(2): 339–67PubMedCrossRef Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009; 87(2): 339–67PubMedCrossRef
93.
go back to reference Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 2008; 188(1): 26–8PubMed Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 2008; 188(1): 26–8PubMed
94.
go back to reference Cleemput I, van WP, Huybrechts M, et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009; 12(4): 441–9PubMedCrossRef Cleemput I, van WP, Huybrechts M, et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009; 12(4): 441–9PubMedCrossRef
95.
go back to reference Vinck I, Neyt M, Thiry N, et al. Introduction of emerging medical devices on the market: a new procedure in Belgium. Int J Technol Assess Health Care 2007; 23(4): 449–54PubMedCrossRef Vinck I, Neyt M, Thiry N, et al. Introduction of emerging medical devices on the market: a new procedure in Belgium. Int J Technol Assess Health Care 2007; 23(4): 449–54PubMedCrossRef
96.
go back to reference Habl C, Antony K, Arts D, et al. Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member states: country profiles. Vienna: European Commission, Osterreichisches Bundesinstitut fur Gesundheitswesen (OBIG), 2006 [online]. Available from URL: http://ec. europa.eu/competition/mergers/studies_reports/oebig.pdf [Accessed 2011 Jun 10] Habl C, Antony K, Arts D, et al. Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member states: country profiles. Vienna: European Commission, Osterreichisches Bundesinstitut fur Gesundheitswesen (OBIG), 2006 [online]. Available from URL: http://​ec.​ europa.eu/competition/mergers/studies_reports/oebig.pdf [Accessed 2011 Jun 10]
97.
go back to reference Health care systems in transition: Belgium. Brussels: European Observatory on Health Care Systems, 2000 [online]. Available from URL: http://www.euro.who.int/ _data/assets/pdf_file/0003/75126/E71203.pdf [Accessed 2011 Jun 10] Health care systems in transition: Belgium. Brussels: European Observatory on Health Care Systems, 2000 [online]. Available from URL: http://​www.​euro.​who.​int/​ _data/assets/pdf_file/0003/75126/E71203.pdf [Accessed 2011 Jun 10]
98.
go back to reference Corens D. Belgium: health system review. Copenhagen: European Observatory on Health Care Systems, WHO Regional Office for Europe, 2007. Health Sys in Transition 2007; 9 (2) [online]. Available from URL: http://www. euro.who.int/__data/assets/pdf_file/0007/96442/E90059. pdf [Accessed 2011 Jun 10] Corens D. Belgium: health system review. Copenhagen: European Observatory on Health Care Systems, WHO Regional Office for Europe, 2007. Health Sys in Transition 2007; 9 (2) [online]. Available from URL: http://​www.​ euro.who.int/__data/assets/pdf_file/0007/96442/E90059. pdf [Accessed 2011 Jun 10]
99.
go back to reference Denis A, Simoens S, Christel F, et al. Belgium. In: Policies for rare diseases and orphan drugs [KCE reports 112C]. Brussels: Belgian Health Care Knowledge Centre, 2009: 35–44 [online]. Available from URL: http://www.kce. fgov.be/Download.aspx?ID=2161 [Accessed 2011 Jun 10] Denis A, Simoens S, Christel F, et al. Belgium. In: Policies for rare diseases and orphan drugs [KCE reports 112C]. Brussels: Belgian Health Care Knowledge Centre, 2009: 35–44 [online]. Available from URL: http://​www.​kce.​ fgov.be/Download.aspx?ID=2161 [Accessed 2011 Jun 10]
100.
go back to reference Giacomini M. How good is good enough? Standards in policy decisions to cover new health technologies. Healthc Policy 2007; 3(2): 91–101PubMed Giacomini M. How good is good enough? Standards in policy decisions to cover new health technologies. Healthc Policy 2007; 3(2): 91–101PubMed
101.
go back to reference Whyte K. PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example. NZ Med J 2005; 118(1226): U1759 Whyte K. PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example. NZ Med J 2005; 118(1226): U1759
102.
go back to reference Manning J, Paterson R. “Prioritization”: rationing health care in New Zealand. J Law Med Ethics 2005; 33(4): 681–97PubMedCrossRef Manning J, Paterson R. “Prioritization”: rationing health care in New Zealand. J Law Med Ethics 2005; 33(4): 681–97PubMedCrossRef
103.
go back to reference O’Donnell JL, Smyth D, Frampton C. Prioritizing healthcare funding. Intern Med J 2005; 35(7): 409–12PubMedCrossRef O’Donnell JL, Smyth D, Frampton C. Prioritizing healthcare funding. Intern Med J 2005; 35(7): 409–12PubMedCrossRef
104.
go back to reference National Health Committee. Decision-making about new health interventions. Wellington: National Health Committee, 2005 [online]. Available from URL: http://www. nhc.health.govt.nz/moh.nsf/indexcm/nhc-new-health-inter ventions [Accessed 2011 Jun 10] National Health Committee. Decision-making about new health interventions. Wellington: National Health Committee, 2005 [online]. Available from URL: http://​www.​ nhc.health.govt.nz/moh.nsf/indexcm/nhc-new-health-inter ventions [Accessed 2011 Jun 10]
105.
go back to reference National Health Committee. District health board decision-making about new health interventions: a background paper. Wellington: National Health Committee, 2006 [online]. Available from URL: http://www.nhc.health. govt.nz/moh.nsf/pagescm/667/$File/dhb-decisions-new-health-background-paper.pdf [Accessed 2011 Jun 10] National Health Committee. District health board decision-making about new health interventions: a background paper. Wellington: National Health Committee, 2006 [online]. Available from URL: http://​www.​nhc.​health.​ govt.nz/moh.nsf/pagescm/667/$File/dhb-decisions-new-health-background-paper.pdf [Accessed 2011 Jun 10]
106.
go back to reference Pharmaceutical Management Agency (PHARMAC). Medicines strategy: submission on consultation document: ‘Towards a medicines strategy’. Wellington: PHARMAC, 2009 [online]. Available from URL: http://www.pharmac. govt.nz/2009/10/12/Consumer%20Participation%20Discus sion.pdf [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Medicines strategy: submission on consultation document: ‘Towards a medicines strategy’. Wellington: PHARMAC, 2009 [online]. Available from URL: http://​www.​pharmac.​ govt.nz/2009/10/12/Consumer%20Participation%20Discus sion.pdf [Accessed 2011 Jun 10]
107.
go back to reference Pharmaceutical Management Agency (PHARMAC). Guidelines for funding applications to PHARMAC. Wellington: PHARMAC, 2009 [online]. Available from URL: http://www.pharmac.govt.nz/2009/12/23/2009-12-23%20-%20 PHARMAC%20notification%20of%20final%20Applica tion%20Guidelines.pdf [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Guidelines for funding applications to PHARMAC. Wellington: PHARMAC, 2009 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​2009/​12/​23/​2009-12-23%20-%20 PHARMAC%20notification%20of%20final%20Applica tion%20Guidelines.pdf [Accessed 2011 Jun 10]
108.
go back to reference Pharmaceutical Management Agency (PHARMAC). Operating policies and procedures of the Pharmaceutical Management Agency (‘PHARMAC’). 3rd ed. Wellington: PHARMAC, 2006 [online]. Available from URL: http://www.pharmac.govt.nz/2005/12/22/231205.pdf [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Operating policies and procedures of the Pharmaceutical Management Agency (‘PHARMAC’). 3rd ed. Wellington: PHARMAC, 2006 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​2005/​12/​22/​231205.​pdf [Accessed 2011 Jun 10]
109.
go back to reference Pharmaceutical Management Agency (PHARMAC). Section H of the pharmaceutical schedule (hospital pharmaceuticals). Wellington: PHARMAC, 2010 [online]. Available from URL: http://www.pharmac.govt.nz/Schedule/SectionH [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Section H of the pharmaceutical schedule (hospital pharmaceuticals). Wellington: PHARMAC, 2010 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​Schedule/​SectionH [Accessed 2011 Jun 10]
110.
go back to reference Pharmaceutical Management Agency (PHARMAC). Online pharmaceutical schedule. Wellington: PHARMAC, 2010 [online]. Available from URL: http://www.phar mac.govt.nz/Schedule [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Online pharmaceutical schedule. Wellington: PHARMAC, 2010 [online]. Available from URL: http://​www.​phar mac.govt.nz/Schedule [Accessed 2011 Jun 10]
111.
go back to reference Pharmaceutical Management Agency (PHARMAC). Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Wellington: PHARMAC, 2007 [online]. Available from URL: http://www.pharmac.govt.nz/ 2007/06/19/PFPAFinal.pdf [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Wellington: PHARMAC, 2007 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​ 2007/06/19/PFPAFinal.pdf [Accessed 2011 Jun 10]
112.
go back to reference Pharmaceutical Management Agency (PHARMAC). Scope of analysis. In: Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Draft. Version 2. Wellington: PHARMAC, 2006: 19–25 [online]. Available from URL: http://www.pharmac.govt.nz/2006/07/ 31/PFPAv2.pdf [Accessed 2011 Jun 10] Pharmaceutical Management Agency (PHARMAC). Scope of analysis. In: Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Draft. Version 2. Wellington: PHARMAC, 2006: 19–25 [online]. Available from URL: http://​www.​pharmac.​govt.​nz/​2006/​07/​ 31/PFPAv2.pdf [Accessed 2011 Jun 10]
113.
go back to reference Grocott R, Metcalfe S. Going against the flow: The impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J 2005; 118(1223): U1690PubMed Grocott R, Metcalfe S. Going against the flow: The impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J 2005; 118(1223): U1690PubMed
114.
go back to reference Martinussen PE, Hagen TP. Reimbursement systems, organisational forms and patient selection: evidence from day surgery in Norway. Health Econ Policy Law 2009; 4 (Pt 2): 139–58PubMedCrossRef Martinussen PE, Hagen TP. Reimbursement systems, organisational forms and patient selection: evidence from day surgery in Norway. Health Econ Policy Law 2009; 4 (Pt 2): 139–58PubMedCrossRef
115.
go back to reference Norwegian Medicines Agency. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Oslo: Statens legemiddelverk/ Norwegian Medicines Agency, 2005 [online]. Available from URL: http://www.legemiddelverket.no/templates/ InterPage____25644.aspx [Accessed 2011 Jun 10] Norwegian Medicines Agency. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Oslo: Statens legemiddelverk/ Norwegian Medicines Agency, 2005 [online]. Available from URL: http://​www.​legemiddelverket​.​no/​templates/​ InterPage____25644.aspx [Accessed 2011 Jun 10]
116.
go back to reference Norwegian Medicines Agency. Application standard for acceptance to the drug reimbursement scheme; pursuant to Article 9 of the regulation on reimbursement of crucial drug costs. Oslo: Statens legemiddelverk/Norwegian Medicines Agency, 2005 [online]. Available from URL: http://www.legemiddelverket.no/templates/InterPage__ 25665.aspx [Accessed 2011 Jun 10] Norwegian Medicines Agency. Application standard for acceptance to the drug reimbursement scheme; pursuant to Article 9 of the regulation on reimbursement of crucial drug costs. Oslo: Statens legemiddelverk/Norwegian Medicines Agency, 2005 [online]. Available from URL: http://​www.​legemiddelverket​.​no/​templates/​InterPage_​_​ 25665.aspx [Accessed 2011 Jun 10]
117.
go back to reference Pharmaceutical pricing and reimbursement information: Norway. Pharma profile: October 2008. Vienna: PPRI, 2008 [online]. Available from URL: http://ppri.oebig.at/ Downloads/Results/Norway_PPRI_2008.pdf [Accessed 2011 Jun 10] Pharmaceutical pricing and reimbursement information: Norway. Pharma profile: October 2008. Vienna: PPRI, 2008 [online]. Available from URL: http://​ppri.​oebig.​at/​ Downloads/Results/Norway_PPRI_2008.pdf [Accessed 2011 Jun 10]
118.
go back to reference Garner S. How decisions on the use of medicines and medical devices are made. Pharmaceutical J 2005; 275(7364): 254–6 Garner S. How decisions on the use of medicines and medical devices are made. Pharmaceutical J 2005; 275(7364): 254–6
119.
go back to reference nternational Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: Scotland. Reimbursement process. Lawrenceville (NJ): ISPOR, 2007 [online]. Available from URL: http://www.ispor.org/HTARoadMaps/Scotland.asp [Accessed 2011 Jun 10] nternational Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: Scotland. Reimbursement process. Lawrenceville (NJ): ISPOR, 2007 [online]. Available from URL: http://​www.​ispor.​org/​HTARoadMaps/​Scotland.​asp [Accessed 2011 Jun 10]
120.
go back to reference International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world: Scotland. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://www.ispor.org/PE guidelines/countrydet.asp?c=19&t=2 [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world: Scotland. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://​www.​ispor.​org/​PE guidelines/countrydet.asp?c=19&t=2 [Accessed 2011 Jun 10]
121.
go back to reference Scottish Medicines Consortium. Templates/guidance for submission. Glasgow: Scottish Medicines Consortium, 2011 [online]. Available from URL: http://www.scottish medicines.org.uk/Submission_Process/Submission_Guid ance_and_Templates_for_Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission [Accessed 2011 Jun 10] Scottish Medicines Consortium. Templates/guidance for submission. Glasgow: Scottish Medicines Consortium, 2011 [online]. Available from URL: http://​www.​scottish medicines.org.uk/Submission_Process/Submission_Guid ance_and_Templates_for_Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission [Accessed 2011 Jun 10]
122.
go back to reference NHS Scotland. SMC Evaluation Project Team. An evaluation of how SMC has engaged with its key stakeholders and shaped medicines use across NHS Scotland: summary report. Glasgow: NHS Scotland/Scottish Medicines Consortium, 2008 [online]. Available from URL: http://www.scottishmedicines.org.uk/files/SMC_Eval1_FINAL_ lores.pdf [Accessed 2011 Jun 10] NHS Scotland. SMC Evaluation Project Team. An evaluation of how SMC has engaged with its key stakeholders and shaped medicines use across NHS Scotland: summary report. Glasgow: NHS Scotland/Scottish Medicines Consortium, 2008 [online]. Available from URL: http://​www.​scottishmedicine​s.​org.​uk/​files/​SMC_​Eval1_​FINAL_​ lores.pdf [Accessed 2011 Jun 10]
123.
go back to reference Scottish Medicines Consortium. Submission process [online]. Available from URL: http://www.scottishmedicines. org.uk/smc/22.html [Accessed 2011 Jun 10] Scottish Medicines Consortium. Submission process [online]. Available from URL: http://​www.​scottishmedicine​s.​ org.uk/smc/22.html [Accessed 2011 Jun 10]
124.
go back to reference Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010 Apr; 11(2): 195–203PubMedCrossRef Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010 Apr; 11(2): 195–203PubMedCrossRef
125.
go back to reference Nygren P, Sandman L. If you are young you get it, but if you are old you are left out: the significance of age for choice of treatment and priorities in cancer care. Lakartidningen 2008; 105(47): 3417–9PubMed Nygren P, Sandman L. If you are young you get it, but if you are old you are left out: the significance of age for choice of treatment and priorities in cancer care. Lakartidningen 2008; 105(47): 3417–9PubMed
126.
go back to reference Jansson S. Implementing accountability for reasonableness: the case of pharmaceutical reimbursement in Sweden. Health Econ Policy Law 2007; 2 (Pt 2): 153–71PubMedCrossRef Jansson S. Implementing accountability for reasonableness: the case of pharmaceutical reimbursement in Sweden. Health Econ Policy Law 2007; 2 (Pt 2): 153–71PubMedCrossRef
127.
go back to reference Faulkner E, Matuszewski K, Niziol C. ISPOR global health care systems road map: Sweden. Lawrenceville (NJ): International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2009 [online]. Available from URL: http://www.ispor.org/HTARoadMaps/Sweden. asp [Accessed 2011 Jun 10] Faulkner E, Matuszewski K, Niziol C. ISPOR global health care systems road map: Sweden. Lawrenceville (NJ): International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2009 [online]. Available from URL: http://​www.​ispor.​org/​HTARoadMaps/​Sweden.​ asp [Accessed 2011 Jun 10]
128.
go back to reference Anell A, Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ 2005; 6(3): 274–9PubMedCrossRef Anell A, Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ 2005; 6(3): 274–9PubMedCrossRef
129.
go back to reference The Swedish Pharmaceutical Benefits Board. Reimbursement review. Stockholm: Tandvards Och Lakemedelsformansverket (TLV), 2009 [online]. Available from URL: http://www.tlv.se/ in-english/reimbursement-review/ [Accessed 2011 Jun 10] The Swedish Pharmaceutical Benefits Board. Reimbursement review. Stockholm: Tandvards Och Lakemedelsformansverket (TLV), 2009 [online]. Available from URL: http://​www.​tlv.​se/​ in-english/reimbursement-review/ [Accessed 2011 Jun 10]
130.
go back to reference The Dental and Pharmaceutical Benefits Agency [formerly the Swedish Pharmaceutical Benefits Board]. Working guidelines for the pharmaceutical reimbursement review. Stockholm: Tandvards-Och Lakemedelsformansverket (TLV), 2008 [online]. Available from URL: http://www. tlv.se/Upload/Genomgangen/guidelines-pharmaceutical-reimbursement.pdf [Accessed 2011 Jun 10] The Dental and Pharmaceutical Benefits Agency [formerly the Swedish Pharmaceutical Benefits Board]. Working guidelines for the pharmaceutical reimbursement review. Stockholm: Tandvards-Och Lakemedelsformansverket (TLV), 2008 [online]. Available from URL: http://​www.​ tlv.se/Upload/Genomgangen/guidelines-pharmaceutical-reimbursement.pdf [Accessed 2011 Jun 10]
131.
go back to reference The Dental and Pharmaceutical Benefits Agency. Welcome to TLV. Stockholm: Tandvards-Och Lakemedelsformansverket (TLV), 2008 [online]. Available from URL: http://www. tlv.se/in-english-old/in-english/ [Accessed 2011 Jun 10] The Dental and Pharmaceutical Benefits Agency. Welcome to TLV. Stockholm: Tandvards-Och Lakemedelsformansverket (TLV), 2008 [online]. Available from URL: http://​www.​ tlv.se/in-english-old/in-english/ [Accessed 2011 Jun 10]
132.
go back to reference The Dental and Pharmaceutical Benefits Agency. Reimbursement review. Stockholm: Tandvards-Och Lakemedelsformansverket (TLV), 2008 [online]. Available from URL: http://www.tlv.se/in-english-old/medicines-new/reimb ursement-review/ [Accessed 2011 Jun 10] The Dental and Pharmaceutical Benefits Agency. Reimbursement review. Stockholm: Tandvards-Och Lakemedelsformansverket (TLV), 2008 [online]. Available from URL: http://​www.​tlv.​se/​in-english-old/​medicines-new/​reimb ursement-review/ [Accessed 2011 Jun 10]
133.
go back to reference The Swedish Pharmaceutical Benefits Board. Guidelines for companies: the Swedish Pharmaceutical Benefits Board (LFN). Stockholm: Lakemedelsformansnamnden (LFN), 2008 [online]. Available from URL: http://www. tlv.se/Upload/English/Guidelines-for-Companies.pdf [Accessed 2011 Jun 10] The Swedish Pharmaceutical Benefits Board. Guidelines for companies: the Swedish Pharmaceutical Benefits Board (LFN). Stockholm: Lakemedelsformansnamnden (LFN), 2008 [online]. Available from URL: http://​www.​ tlv.se/Upload/English/Guidelines-for-Companies.pdf [Accessed 2011 Jun 10]
134.
go back to reference Sorenson C. The role of HTA in coverage and pricing decisions: a cross-country comparison. Euro Observer: the Health Policy Bulletin of the European Observatory on Health Systems and Policies 2009; 11(1): 1–12 [online]. Available from URL: http://www.euro.who.int/__data/ assets/pdf_file/0019/80335/EuroObserver_spring2009.pdf [Accessed 2011 Jun 10] Sorenson C. The role of HTA in coverage and pricing decisions: a cross-country comparison. Euro Observer: the Health Policy Bulletin of the European Observatory on Health Systems and Policies 2009; 11(1): 1–12 [online]. Available from URL: http://​www.​euro.​who.​int/​_​_​data/​ assets/pdf_file/0019/80335/EuroObserver_spring2009.pdf [Accessed 2011 Jun 10]
135.
go back to reference European Commission, Health and Consumer Protection Directorate-General and Austrian Ministry of Health, Family and Youth. Pharmaceutical pricing and reimbursement information: Sweden. Pharma profile, final version, June 2007. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI), 2007 [online]. Available from URL: http://ppri.oebig.at/Downloads/Results/Sweden_P PRI_2007.pdf [Accessed 2011 Jun 10] European Commission, Health and Consumer Protection Directorate-General and Austrian Ministry of Health, Family and Youth. Pharmaceutical pricing and reimbursement information: Sweden. Pharma profile, final version, June 2007. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI), 2007 [online]. Available from URL: http://​ppri.​oebig.​at/​Downloads/​Results/​Sweden_​P PRI_2007.pdf [Accessed 2011 Jun 10]
136.
go back to reference National Institute for Health and Clinical Excellence. Appraising treatments which may extend life, at the end of life. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/devnicetech/ endoflifetreatments.jsp [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Appraising treatments which may extend life, at the end of life. London: NICE, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​aboutnice/​howwework/​devnicetech/​ endoflifetreatments.jsp [Accessed 2011 Jun 10]
137.
go back to reference All Wales Medicines Strategy Group. Independent review process (IR). Vale of Glamorgan: All Wales Medicines Strategy Group, 2007 [online]. Available from URL: http://www.wales.nhs.uk/sites3/Documents/371/Independent %20Review%20process%20_fina%20for%20website_.pdf [Accessed 2011 Jun 10] All Wales Medicines Strategy Group. Independent review process (IR). Vale of Glamorgan: All Wales Medicines Strategy Group, 2007 [online]. Available from URL: http://​www.​wales.​nhs.​uk/​sites3/​Documents/​371/​Independent %20Review%20process%20_fina%20for%20website_.pdf [Accessed 2011 Jun 10]
138.
go back to reference All Wales Medicines Strategy Group. Structure of appraisal. Vale of Glamorgan: All Wales Medicines Strategy Group, 2007 [online]. Available from URL: http://www. wales.nhs.uk/sites3/Documents/371/Guidelines%20for% 20appraising%20medicines.pdf [Accessed 2011 Jun 10] All Wales Medicines Strategy Group. Structure of appraisal. Vale of Glamorgan: All Wales Medicines Strategy Group, 2007 [online]. Available from URL: http://​www.​ wales.nhs.uk/sites3/Documents/371/Guidelines%20for% 20appraising%20medicines.pdf [Accessed 2011 Jun 10]
139.
go back to reference All Wales Medicines Strategy Group. Vale of Glamorgan: Welsh Medicines Partnership, 2010 [online]. Available from URL: http://www.wales.nhs.uk/sites3/home.cfm? orgid=371 [Accessed 2011 Jun 10] All Wales Medicines Strategy Group. Vale of Glamorgan: Welsh Medicines Partnership, 2010 [online]. Available from URL: http://​www.​wales.​nhs.​uk/​sites3/​home.​cfm?​ orgid=371 [Accessed 2011 Jun 10]
140.
go back to reference Healy P, Pugatch M. Theory versus practice: discussing the governance of health technology assessment systems. Stockholm: Stockholm Network, 2009 [online]. Available from URL: http://www.stockholm-network.org/downloads/pub lications/Theory_versus_Practice.pdf [Accessed 2011 Jun 10] Healy P, Pugatch M. Theory versus practice: discussing the governance of health technology assessment systems. Stockholm: Stockholm Network, 2009 [online]. Available from URL: http://​www.​stockholm-network.​org/​downloads/​pub lications/Theory_versus_Practice.pdf [Accessed 2011 Jun 10]
141.
go back to reference Stolk EA, de BA, van Halteren AR, et al. Role of health technology assessment in shaping the benefits package in the Netherlands. Expert Rev Pharmacoecon Outcomes Res 2009; 9(1): 85–94PubMedCrossRef Stolk EA, de BA, van Halteren AR, et al. Role of health technology assessment in shaping the benefits package in the Netherlands. Expert Rev Pharmacoecon Outcomes Res 2009; 9(1): 85–94PubMedCrossRef
142.
go back to reference Bozic KJ. Health policy and practice management issues in orthopaedic surgery: editorial comment. Clin Orthop Relat Res 2007; 457: 2PubMedCrossRef Bozic KJ. Health policy and practice management issues in orthopaedic surgery: editorial comment. Clin Orthop Relat Res 2007; 457: 2PubMedCrossRef
143.
go back to reference Niezen M, de BA, Stolk E, et al. Conditional reimbursement within the Dutch drug policy. Health Policy 2007; 84(1): 39–50PubMedCrossRef Niezen M, de BA, Stolk E, et al. Conditional reimbursement within the Dutch drug policy. Health Policy 2007; 84(1): 39–50PubMedCrossRef
144.
go back to reference Stolk EA, Rutten FF. The “health benefit basket” in the Netherlands. Eur J Health Econ 2005 Dec; Suppl.: 53–7 Stolk EA, Rutten FF. The “health benefit basket” in the Netherlands. Eur J Health Econ 2005 Dec; Suppl.: 53–7
145.
go back to reference Stolk EA, Poley MJ. Criteria for determining a basic health services package: recent developments in the Netherlands. Eur J Health Econ 2005; 6(1): 2–7PubMedCrossRef Stolk EA, Poley MJ. Criteria for determining a basic health services package: recent developments in the Netherlands. Eur J Health Econ 2005; 6(1): 2–7PubMedCrossRef
146.
go back to reference Postma MJ. Public health economics of vaccines in the Netherlands: methodological issues and applications. J Public Health 2008; 16(4): 267–73CrossRef Postma MJ. Public health economics of vaccines in the Netherlands: methodological issues and applications. J Public Health 2008; 16(4): 267–73CrossRef
147.
go back to reference de Bont A, Zandwijken G, Stolk E, et al. Prioritisation by physicians in the Netherlands: the growth hormone example in drug reimbursement decisions. Health Policy 2007; 80(3): 369–77PubMedCrossRef de Bont A, Zandwijken G, Stolk E, et al. Prioritisation by physicians in the Netherlands: the growth hormone example in drug reimbursement decisions. Health Policy 2007; 80(3): 369–77PubMedCrossRef
148.
go back to reference Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care: the role of health technology assessment in the European Union [European Observatory on Health Systems and Policies. Observatory Studies Series No. 11]. Copenhagen: WHO, 2008 [online]. Available from URL: http://www.euro.who.int/__data/assets/ pdf_file/0011/98291/E91271.pdf [Accessed 2011 Jun 10] Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care: the role of health technology assessment in the European Union [European Observatory on Health Systems and Policies. Observatory Studies Series No. 11]. Copenhagen: WHO, 2008 [online]. Available from URL: http://​www.​euro.​who.​int/​_​_​data/​assets/​ pdf_file/0011/98291/E91271.pdf [Accessed 2011 Jun 10]
149.
go back to reference International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: the Netherlands. Reimbursement process. Lawrenceville (NJ): ISPOR, 2007 [online]. Available from URL: http://www.ispor.org/HTARoadMaps/Netherlands.asp [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: the Netherlands. Reimbursement process. Lawrenceville (NJ): ISPOR, 2007 [online]. Available from URL: http://​www.​ispor.​org/​HTARoadMaps/​Netherlands.​asp [Accessed 2011 Jun 10]
150.
go back to reference Postma TJ, Alers JC, Terpstra S, et al. Medical technology decisions in the Netherlands: how to solve the dilemma of technology foresight versus market research? Technol Forecast Soc Change 2007; 74: 1823–33CrossRef Postma TJ, Alers JC, Terpstra S, et al. Medical technology decisions in the Netherlands: how to solve the dilemma of technology foresight versus market research? Technol Forecast Soc Change 2007; 74: 1823–33CrossRef
151.
go back to reference Schafer W, Kroneman M, Boerma W, et al. The Netherlands: health system review [Health Systems in Transition]. Copenhagen: European Observatory on Health Care Systems, WHO Regional Office for Europe, 2010 [online]. Available from URL: http://www.euro.who.int/en/home/ projects/observatory/publications/health-system-profiles-hits/full-list-of-hits/netherlands-hit-2010 [Accessed 2011 Jun 10] Schafer W, Kroneman M, Boerma W, et al. The Netherlands: health system review [Health Systems in Transition]. Copenhagen: European Observatory on Health Care Systems, WHO Regional Office for Europe, 2010 [online]. Available from URL: http://​www.​euro.​who.​int/​en/​home/​ projects/observatory/publications/health-system-profiles-hits/full-list-of-hits/netherlands-hit-2010 [Accessed 2011 Jun 10]
152.
go back to reference Akkerman AE, Kuyvenhoven MM, Verheij TJ, et al. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharma-coepidemiol Drug Saf 2008; 17(4): 378–83CrossRef Akkerman AE, Kuyvenhoven MM, Verheij TJ, et al. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharma-coepidemiol Drug Saf 2008; 17(4): 378–83CrossRef
153.
go back to reference de Wolf P, Brouwer WB, Rutten FF. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int J Health Plann Manage 2005; 20(4): 351–74PubMedCrossRef de Wolf P, Brouwer WB, Rutten FF. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int J Health Plann Manage 2005; 20(4): 351–74PubMedCrossRef
154.
go back to reference van Nooten F, van Agthoven M. Mandatory pharmaco-economic studies in the Dutch reimbursement setting. Institute for Medical Technology Assessment (iMTA) Newsletter 2005; 3 (1 May): 1–3 [online]. Available from URL: http://www.imta.nl/publications/imta_newsletter_ 3_1.pdf [Accessed 2011 Jun 10] van Nooten F, van Agthoven M. Mandatory pharmaco-economic studies in the Dutch reimbursement setting. Institute for Medical Technology Assessment (iMTA) Newsletter 2005; 3 (1 May): 1–3 [online]. Available from URL: http://​www.​imta.​nl/​publications/​imta_​newsletter_​ 3_1.pdf [Accessed 2011 Jun 10]
155.
go back to reference Peters A. Dutch health insurance recommends conditional reimbursement of Januvia and Procoralan. APM Health Europe 2007 [online]. Available from URL: http://www. apmhealtheurope.com/story.php?mots=PROCORALAN& searchScope=1&searchType=0&numero=L7697 [Accessed 2011 Jun 10] Peters A. Dutch health insurance recommends conditional reimbursement of Januvia and Procoralan. APM Health Europe 2007 [online]. Available from URL: http://​www.​ apmhealtheurope.com/story.php?mots=PROCORALAN& searchScope=1&searchType=0&numero=L7697 [Accessed 2011 Jun 10]
156.
go back to reference Chalkidou K. Comparative effectiveness review within the UK’s National Institute for Health and Clinical Excellence. Issue Brief (Commonw Fund) 2009; 59: 1–12 Chalkidou K. Comparative effectiveness review within the UK’s National Institute for Health and Clinical Excellence. Issue Brief (Commonw Fund) 2009; 59: 1–12
157.
go back to reference Karnon J, Carlton J, Czoski-Murray C, et al. Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier? Appl Health Econ Health Policy 2009; 7(1): 1–9PubMedCrossRef Karnon J, Carlton J, Czoski-Murray C, et al. Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier? Appl Health Econ Health Policy 2009; 7(1): 1–9PubMedCrossRef
158.
go back to reference Mason AR, Drummond MF. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 2009; 45(7): 1188–92PubMedCrossRef Mason AR, Drummond MF. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 2009; 45(7): 1188–92PubMedCrossRef
159.
go back to reference Parrish A, Blockman M. Clinical excellence and the NIC-Eties of value-based priority setting. S Afr Med J 2008; 98(10): 758, 760–61 Parrish A, Blockman M. Clinical excellence and the NIC-Eties of value-based priority setting. S Afr Med J 2008; 98(10): 758, 760–61
160.
go back to reference Syrett K. NICE and judicial review: enforcing ‘accountability for reasonableness’ through the courts? Med Law Rev 2008; 16(1): 127–40PubMedCrossRef Syrett K. NICE and judicial review: enforcing ‘accountability for reasonableness’ through the courts? Med Law Rev 2008; 16(1): 127–40PubMedCrossRef
161.
go back to reference Williams IP, Bryan S. Cost-effectiveness analysis and formulary decision making in England: findings from research. Soc Sci Med 2007; 65(10): 2116–29PubMedCrossRef Williams IP, Bryan S. Cost-effectiveness analysis and formulary decision making in England: findings from research. Soc Sci Med 2007; 65(10): 2116–29PubMedCrossRef
162.
163.
go back to reference Supporting rational local decision-making about medicines (and treatments): a handbook of good practice guidance. 1st ed. Liverpool (UK): National Prescribing Centre, 2009 [online]. Available from URL: http://www.medlaw.eu/ nhs_guidance/NHS_handbook_complete.pdf [Accessed 2011 Jun 10] Supporting rational local decision-making about medicines (and treatments): a handbook of good practice guidance. 1st ed. Liverpool (UK): National Prescribing Centre, 2009 [online]. Available from URL: http://​www.​medlaw.​eu/​ nhs_guidance/NHS_handbook_complete.pdf [Accessed 2011 Jun 10]
164.
go back to reference Useful sources of information for area prescribing and medicines management committees (APCs). Liverpool: National Prescribing Centre, 2009 [online]. Available from URL: http://www.npc.co.uk/local_decision_making/ resources/apc_guide_resources.pdf [Accessed 2011 Jun 10] Useful sources of information for area prescribing and medicines management committees (APCs). Liverpool: National Prescribing Centre, 2009 [online]. Available from URL: http://​www.​npc.​co.​uk/​local_​decision_​making/​ resources/apc_guide_resources.pdf [Accessed 2011 Jun 10]
165.
go back to reference Defining guiding principles for processes supporting local decision making about medicines. Final report. Liverpool: National Prescribing Centre, 2009 [online]. Available from URL: http://www.medlaw.eu/nhs_guidance/ Medlaw-DH_Defining_Guiding_Principles_for_Processes_ supporting_Local_Decision_Making_about_Medicines_ Report.pdf [Accessed 2011 Jun 10] Defining guiding principles for processes supporting local decision making about medicines. Final report. Liverpool: National Prescribing Centre, 2009 [online]. Available from URL: http://​www.​medlaw.​eu/​nhs_​guidance/​ Medlaw-DH_Defining_Guiding_Principles_for_Processes_ supporting_Local_Decision_Making_about_Medicines_ Report.pdf [Accessed 2011 Jun 10]
166.
go back to reference Reeve S. Directions to primary care trusts and NHS trusts concerning decisions about drugs and other treatments 2009. London: Department of Health, 2009 [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsand statistics/Publications/PublicationsLegislation/DH_096067 [Accessed 2011 Jun 10] Reeve S. Directions to primary care trusts and NHS trusts concerning decisions about drugs and other treatments 2009. London: Department of Health, 2009 [online]. Available from URL: http://​www.​dh.​gov.​uk/​en/​Publicationsand statistics/Publications/PublicationsLegislation/DH_096067 [Accessed 2011 Jun 10]
167.
go back to reference Brambleby P, Jackson A, Muir Gray JA. Programme-based decision-making for better value healthcare: second annual population value review. Oxford (UK): NHS National Knowledge Service, 2008 [online]. Available from URL: http://www.childrenstrustcommissioning.com/cs/ media/p/1641.aspx [Accessed 2011 Jun 10] Brambleby P, Jackson A, Muir Gray JA. Programme-based decision-making for better value healthcare: second annual population value review. Oxford (UK): NHS National Knowledge Service, 2008 [online]. Available from URL: http://​www.​childrenstrustco​mmissioning.​com/​cs/​ media/p/1641.aspx [Accessed 2011 Jun 10]
168.
go back to reference International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: United Kingdom. Diagnostics. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://www. ispor.org/htaroadmaps/UKDiagnostics.asp [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: United Kingdom. Diagnostics. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://​www.​ ispor.org/htaroadmaps/UKDiagnostics.asp [Accessed 2011 Jun 10]
169.
go back to reference International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: United Kingdom (England and Wales). Reimbursemment process. Lawrenceville (NJ): ISPOR, 2008 [online]. Available from URL: http://www.ispor.org/htaroadmaps/ UK.asp [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map: United Kingdom (England and Wales). Reimbursemment process. Lawrenceville (NJ): ISPOR, 2008 [online]. Available from URL: http://​www.​ispor.​org/​htaroadmaps/​ UK.asp [Accessed 2011 Jun 10]
170.
go back to reference Financing medical devices in Europe: executive summary. Belgium: The European Health Technology Institute for Socio-Economic Research (EHTI), 2009 [online]. Available from URL: http://www.together4healthinnovation. eu/uploads/Executive%20Summary%20Topic%20I%20 Financing%20Medical%20Devices%20in%20Europe.pdf [Accessed 2011 Jun 10] Financing medical devices in Europe: executive summary. Belgium: The European Health Technology Institute for Socio-Economic Research (EHTI), 2009 [online]. Available from URL: http://​www.​together4healthi​nnovation.​ eu/uploads/Executive%20Summary%20Topic%20I%20 Financing%20Medical%20Devices%20in%20Europe.pdf [Accessed 2011 Jun 10]
171.
go back to reference International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world: British Medical Journal. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://www. ispor.org/PEguidelines/countrydet.asp?c=4&t=2 [Accessed 2011 Jun 10] International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world: British Medical Journal. Lawrenceville (NJ): ISPOR, 2010 [online]. Available from URL: http://​www.​ ispor.org/PEguidelines/countrydet.asp?c=4&t=2 [Accessed 2011 Jun 10]
172.
go back to reference National Institute for Health and Clinical Excellence. Single technology appraisal (STA): specification for manufacturer/ sponsor submission of evidence. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/media/ 59C/B3/SpecificationForManufacturerSponsorSubmission EvidenceJune2010.doc [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Single technology appraisal (STA): specification for manufacturer/ sponsor submission of evidence. London: NICE, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​media/​ 59C/B3/SpecificationForManufacturerSponsorSubmission EvidenceJune2010.doc [Accessed 2011 Jun 10]
173.
go back to reference National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/media/913/06/Guide_to_the_STA-proof_6-26-10-09.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​media/​913/​06/​Guide_​to_​the_​STA-proof_​6-26-10-09.​pdf [Accessed 2011 Jun 10]
174.
go back to reference National Institute for Health and Clinical Excellence. Guide to the multiple technology appraisal process. London: NICE, 2009 [online]. Available from URL: http://www.nice. org.uk/media/916/6B/Guide_to_the_MTA-proof_8-26-10-09. pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Guide to the multiple technology appraisal process. London: NICE, 2009 [online]. Available from URL: http://​www.​nice.​ org.uk/media/916/6B/Guide_to_the_MTA-proof_8-26-10-09. pdf [Accessed 2011 Jun 10]
175.
go back to reference McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 2010; 340: c1786PubMedCrossRef McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 2010; 340: c1786PubMedCrossRef
176.
go back to reference National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. London: NICE, 2009 [online]. Available from URL: http://www. nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL. pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. London: NICE, 2009 [online]. Available from URL: http://​www.​ nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL. pdf [Accessed 2011 Jun 10]
177.
go back to reference Jackson TJ. Health technology assessment in Australia: challenges ahead. Med J Aust 2007; 187(5): 262–4PubMed Jackson TJ. Health technology assessment in Australia: challenges ahead. Med J Aust 2007; 187(5): 262–4PubMed
178.
go back to reference Department of Health and Ageing. The Allen Consulting Group: description of selected health technology assessment processes. Chapter 5: linkages between TGA, MSAC and PDC. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2009 [online]. Available from URL: http://www.health.gov.au/in ternet/main/publishing.nsf/Content/allenreport_TOC∼ allenreport-ch5 [Accessed 2011 Jun 10] Department of Health and Ageing. The Allen Consulting Group: description of selected health technology assessment processes. Chapter 5: linkages between TGA, MSAC and PDC. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​in ternet/main/publishing.nsf/Content/allenreport_TOC∼ allenreport-ch5 [Accessed 2011 Jun 10]
179.
go back to reference Department of Health and Ageing. The Allen Consulting Group: description of selected health technology assessment processes. Chapter 1: overview of health technology assessment. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2009 [online]. Available from URL: http://www.health.gov.au/internet/main/ publishing.nsf/Content/allenreport_TOC≈allenreport-ch1 [Accessed 2011 Jun 10] Department of Health and Ageing. The Allen Consulting Group: description of selected health technology assessment processes. Chapter 1: overview of health technology assessment. Canberra (ACT): Government of Australia, Department of Health and Ageing, 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​main/​ publishing.nsf/Content/allenreport_TOC≈allenreport-ch1 [Accessed 2011 Jun 10]
180.
go back to reference Consumers Health Forum of Australia. Information paper: new health technologies, medical devices and prostheses. Canberra (ACT): Consumers Health Forum of Australia, 2007 [online]. Available from URL: http://www. chf.org.au/pdfs/cns/cns-462-new-health-technologies.pdf [Accessed 2011 Jun 10] Consumers Health Forum of Australia. Information paper: new health technologies, medical devices and prostheses. Canberra (ACT): Consumers Health Forum of Australia, 2007 [online]. Available from URL: http://​www.​ chf.org.au/pdfs/cns/cns-462-new-health-technologies.pdf [Accessed 2011 Jun 10]
181.
go back to reference Medical Services Advisory Committee. Funding for new medical technologies and procedures: application and assessment guidelines. Canberra (ACT): Medical Services Advisory Committee, 2005 [online]. Available from URL: http://www.health.gov.au/internet/msac/publishing.nsf/ Content/D81BE529B98B3DB6CA2575AD0082FD1B/ $File/guidelines.pdf [Accessed 2011 Jun 10] Medical Services Advisory Committee. Funding for new medical technologies and procedures: application and assessment guidelines. Canberra (ACT): Medical Services Advisory Committee, 2005 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​msac/​publishing.​nsf/​ Content/D81BE529B98B3DB6CA2575AD0082FD1B/ $File/guidelines.pdf [Accessed 2011 Jun 10]
182.
go back to reference Economics section of the MSAC guidelines. Canberra (ACT): Medical Services Advisory Committee, 2008 [online]. Available from URL: http://www.health.gov.au/in ternet/msac/publishing.nsf/Content/D81BE529B98B3DB 6CA2575AD0082FD1B/$File/Economics%20Glines%20-%20FINAL%20at%20Aug%202008%20-%20endorsed%20 MSAC%20ESC%20June%202009.pdf [Accessed 2011 Jun 10] Economics section of the MSAC guidelines. Canberra (ACT): Medical Services Advisory Committee, 2008 [online]. Available from URL: http://​www.​health.​gov.​au/​in ternet/msac/publishing.nsf/Content/D81BE529B98B3DB 6CA2575AD0082FD1B/$File/Economics%20Glines%20-%20FINAL%20at%20Aug%202008%20-%20endorsed%20 MSAC%20ESC%20June%202009.pdf [Accessed 2011 Jun 10]
183.
go back to reference Medical Services Advisory Committee performance report 2008–09. Canberra (ACT): Medical Services Advisory Committee, 2009 [online]. Available from URL: http://www.health.gov.au/internet/msac/publishing.nsf/Content/ 9FD4C2646B76FA43CA25768F00221A26/$File/MSAC_ Performance%20_Report_2008–09.pdf [Accessed 2011 Jun 10] Medical Services Advisory Committee performance report 2008–09. Canberra (ACT): Medical Services Advisory Committee, 2009 [online]. Available from URL: http://​www.​health.​gov.​au/​internet/​msac/​publishing.​nsf/​Content/​ 9FD4C2646B76FA43CA25768F00221A26/$File/MSAC_ Performance%20_Report_2008–09.pdf [Accessed 2011 Jun 10]
184.
go back to reference Medical Services Advisory Committee. Guidelines for the assessment of diagnostic technologies. Canberra (ACT): Medical Services Advisory Committee (MSAC), 2005 [online]. Available from URL: http://www.health.gov.au/ internet/msac/publishing.nsf/Content/D81BE529B98B3D B6CA2575AD0082FD1B/$File/Diag%20Guidelines%20Sept %202005%20updated%2021%20may%202007.pdf [Accessed 2011 Jun 10] Medical Services Advisory Committee. Guidelines for the assessment of diagnostic technologies. Canberra (ACT): Medical Services Advisory Committee (MSAC), 2005 [online]. Available from URL: http://​www.​health.​gov.​au/​ internet/msac/publishing.nsf/Content/D81BE529B98B3D B6CA2575AD0082FD1B/$File/Diag%20Guidelines%20Sept %202005%20updated%2021%20may%202007.pdf [Accessed 2011 Jun 10]
185.
go back to reference Australian Government, Department of Health and Ageing. Proposal for changes to the Medical Services Advisory Committee (MSAC) processes for applications for public funding. 2011 [online]. Available from URL: http://www.msac.gov.au/internet/msac/publishing.nsf/content/ home-1/$File/MSAC%20Discussion%20Paper.pdf [Accessed 2011 Jun 10] Australian Government, Department of Health and Ageing. Proposal for changes to the Medical Services Advisory Committee (MSAC) processes for applications for public funding. 2011 [online]. Available from URL: http://​www.​msac.​gov.​au/​internet/​msac/​publishing.​nsf/​content/​ home-1/$File/MSAC%20Discussion%20Paper.pdf [Accessed 2011 Jun 10]
186.
go back to reference National Institute for Clinical Excellence. Guidance on the use of trastuzumab for the treatment of advanced breast cancer [Technology Appraisal Guidance No. 34]. London: NICE, 2002 [online]. Available from URL: http://www. nice.org.uk/nicemedia/pdf/advancedbreastcancerno34PDF. pdf [Accessed 2011 Jun 10] National Institute for Clinical Excellence. Guidance on the use of trastuzumab for the treatment of advanced breast cancer [Technology Appraisal Guidance No. 34]. London: NICE, 2002 [online]. Available from URL: http://​www.​ nice.org.uk/nicemedia/pdf/advancedbreastcancerno34PDF. pdf [Accessed 2011 Jun 10]
187.
go back to reference National Institute for Health and Clinical Excellence. Appeal by Aventis against guidance on taxanes for breast cancer. London: NICE, 2000 [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action= article&r=true&o=32042 [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Appeal by Aventis against guidance on taxanes for breast cancer. London: NICE, 2000 [online]. Available from URL: http://​www.​nice.​org.​uk/​guidance/​index.​jsp?​action=​ article&r=true&o=32042 [Accessed 2011 Jun 10]
188.
go back to reference National Institute for Health and Clinical Excellence. Appraisal of the use of taxanes for the treatment of breast and ovarian cancer. Decision of the appeal panel, May 2000. London: NICE, 2000 [online]. Available from URL: http://www.nice.org.uk/oldsite/appraisals/tax_appeal.htm [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Appraisal of the use of taxanes for the treatment of breast and ovarian cancer. Decision of the appeal panel, May 2000. London: NICE, 2000 [online]. Available from URL: http://​www.​nice.​org.​uk/​oldsite/​appraisals/​tax_​appeal.​htm [Accessed 2011 Jun 10]
189.
go back to reference National Institute for Health and Clinical Excellence. Final appraisal determination (FAD): bevacizumab (Avastin) and cetuximab (Erbitux) for metastatic colorectal cancer [letter from Bowel Cancer UK & Cancerbackup]. London: NICE, 2006 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11611/33913/33913.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Final appraisal determination (FAD): bevacizumab (Avastin) and cetuximab (Erbitux) for metastatic colorectal cancer [letter from Bowel Cancer UK & Cancerbackup]. London: NICE, 2006 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​live/​11611/​33913/​33913.​pdf [Accessed 2011 Jun 10]
190.
go back to reference Bowel Cancer UK response to NICE [e-mail to Emily Marschke, 5 September, 2006]. London: Bowel Cancer UK, 2006 [online]. Available from URL: http://www.nice.org.uk/ nicemedia/live/11611/33881/33881.pdf [Accessed 2011Jun10] Bowel Cancer UK response to NICE [e-mail to Emily Marschke, 5 September, 2006]. London: Bowel Cancer UK, 2006 [online]. Available from URL: http://​www.​nice.​org.​uk/​ nicemedia/live/11611/33881/33881.pdf [Accessed 2011Jun10]
191.
go back to reference Joshi VK. Final appraisal determination (FAD) appeal by the Mouth Cancer Foundation [letter]. London: NICE, 2007 [online]. Available from URL: http://www.nice.org. uk/nicemedia/live/11697/36815/36815.pdf [Accessed 2011 Jun 10] Joshi VK. Final appraisal determination (FAD) appeal by the Mouth Cancer Foundation [letter]. London: NICE, 2007 [online]. Available from URL: http://​www.​nice.​org.​ uk/nicemedia/live/11697/36815/36815.pdf [Accessed 2011 Jun 10]
192.
go back to reference National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Advice on lapatinib for the treatment of women with previously treated advanced or metastatic breast cancer. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/ni cemedia/live/11902/40342/40342.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Advice on lapatinib for the treatment of women with previously treated advanced or metastatic breast cancer. London: NICE, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​ni cemedia/live/11902/40342/40342.pdf [Accessed 2011 Jun 10]
193.
go back to reference GlaxoSmithKline. Re: Appeal by GlaxoSmithKline Limited in respect of the final appraisal determination for lapatinib for the treatment of women with previously treated advanced or metastatic breast cancer. Middlesex: GSK, 2009 [online]. Available from URL: http://www.nice.org.uk/nice media/live/11731/44499/44499.pdf [Accessed 2011 Jun 10] GlaxoSmithKline. Re: Appeal by GlaxoSmithKline Limited in respect of the final appraisal determination for lapatinib for the treatment of women with previously treated advanced or metastatic breast cancer. Middlesex: GSK, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​nice media/live/11731/44499/44499.pdf [Accessed 2011 Jun 10]
194.
go back to reference National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Bevacizumab (first-line), sorafenib (first and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/RenalCellCar cinomaAppealDecision.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Bevacizumab (first-line), sorafenib (first and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. London: NICE, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​pdf/​RenalCellCar cinomaAppealDecision.pdf [Accessed 2011 Jun 10]
195.
go back to reference Roche Products Limited. Notice of appeal by Roche Products Limited: bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma. 2009 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11817/44833/ 44833.pdf [Accessed 2011 Jun 10] Roche Products Limited. Notice of appeal by Roche Products Limited: bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma. 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​live/​11817/​44833/​ 44833.pdf [Accessed 2011 Jun 10]
196.
go back to reference James Whale Fund for Kidney Cancer. Appeal against the final appraisal determination document: bevacizumab, sorafenib, sunitinib (second-line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma. Cambridge: James Whale Fund for Kidney Cancer, 2009 [online]. Available from URL: http://www.nice. org.uk/nicemedia/live/11817/44843/44843.pdf [Accessed 2011 Jun 10] James Whale Fund for Kidney Cancer. Appeal against the final appraisal determination document: bevacizumab, sorafenib, sunitinib (second-line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma. Cambridge: James Whale Fund for Kidney Cancer, 2009 [online]. Available from URL: http://​www.​nice.​ org.uk/nicemedia/live/11817/44843/44843.pdf [Accessed 2011 Jun 10]
197.
go back to reference Notice of appeal: final appraisal determination regarding Nexavar. Bayer HealthCare/Bayer Schering Pharma, 2009 [online]. Available from URL: http://www.nice.org.uk/ni-cemedia/live/12019/47562/47562.pdf [Accessed 2011 Jun 10] Notice of appeal: final appraisal determination regarding Nexavar. Bayer HealthCare/Bayer Schering Pharma, 2009 [online]. Available from URL: http://​www.​nice.​org.​uk/​ni-cemedia/​live/​12019/​47562/​47562.​pdf [Accessed 2011 Jun 10]
198.
go back to reference National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Sorafenib for the treatment of advanced hepatocellular carcinoma. London: NICE, 2010 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12019/48943/48943. pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Sorafenib for the treatment of advanced hepatocellular carcinoma. London: NICE, 2010 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​live/​12019/​48943/​48943.​ pdf [Accessed 2011 Jun 10]
199.
go back to reference National Institute for Clinical Excellence. Appraisal of the use of beta interferons and glatiramer acetate in the treatment of multiple sclerosis: decision of the Appeal Panel. London: NICE, 2001 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11440/32260/32260. pdf [Accessed 2011 Jun 10] National Institute for Clinical Excellence. Appraisal of the use of beta interferons and glatiramer acetate in the treatment of multiple sclerosis: decision of the Appeal Panel. London: NICE, 2001 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​live/​11440/​32260/​32260.​ pdf [Accessed 2011 Jun 10]
200.
go back to reference National Institute for Clinical Excellence. Appraisal of the use of anakinra for the treatment of rheumatoid arthritis: decision of the Appeal Panel. London: NICE, 2003 [online]. Available from URL: http://www.nice.org.uk/nice media/live/11521/32795/32795.pdf [Accessed 2011 Jun 10] National Institute for Clinical Excellence. Appraisal of the use of anakinra for the treatment of rheumatoid arthritis: decision of the Appeal Panel. London: NICE, 2003 [online]. Available from URL: http://​www.​nice.​org.​uk/​nice media/live/11521/32795/32795.pdf [Accessed 2011 Jun 10]
201.
go back to reference National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Advice on adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor (sequential use). London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/ pdf/RheumatoidArthritisAdalimumabAppealPanelDecision. pdf [Accessed 2011 Jun National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Advice on adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor (sequential use). London: NICE, 2008 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​ pdf/RheumatoidArthritisAdalimumabAppealPanelDecision. pdf [Accessed 2011 Jun
202.
go back to reference Arthritis and Musculoskeletal Alliance (ARMA): appeal to NICE [letter]. London: ARMA, 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11902/ 42176/42176.pdf [Accessed 2011 Jun 10] Arthritis and Musculoskeletal Alliance (ARMA): appeal to NICE [letter]. London: ARMA, 2008 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​live/​11902/​ 42176/42176.pdf [Accessed 2011 Jun 10]
203.
go back to reference National Institute for Health and Clinical Excellence. Final appraisal determination: adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor. London: NICE, 2008 [online]. Available from URL: http://www.nice. org.uk/nicemedia/live/11902/41284/41284.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Final appraisal determination: adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor. London: NICE, 2008 [online]. Available from URL: http://​www.​nice.​ org.uk/nicemedia/live/11902/41284/41284.pdf [Accessed 2011 Jun 10]
204.
go back to reference National Rheumatoid Arthritis Society. NRAS appeal against final appraisal document sequential use of adalimumab, etanercept and infliximab for the treatment of RA. Maidenhead: NRAS, 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11902/42181/ 42181.pdf [Accessed 2011 Jun 10] National Rheumatoid Arthritis Society. NRAS appeal against final appraisal document sequential use of adalimumab, etanercept and infliximab for the treatment of RA. Maidenhead: NRAS, 2008 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​live/​11902/​42181/​ 42181.pdf [Accessed 2011 Jun 10]
205.
go back to reference National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/nicemedia/ live/11680/38603/38603.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​ live/11680/38603/38603.pdf [Accessed 2011 Jun 10]
206.
go back to reference National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/nice media/live/11704/38602/38602.pdf[Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Health technology appraisal: appeal hearing. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007 [online]. Available from URL: http://​www.​nice.​org.​uk/​nice media/live/11704/38602/38602.pdf[Accessed 2011 Jun 10]
207.
go back to reference National Institute for Health and Clinical Excellence. Osteoporosis: primary prevention. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2010 [online]. Available from URL: http://guidance.nice.org.uk/TA160 [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Osteoporosis: primary prevention. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2010 [online]. Available from URL: http://​guidance.​nice.​org.​uk/​TA160 [Accessed 2011 Jun 10]
208.
go back to reference Appeal takes place against NICE osteoporosis decision which restricts access to effective medicines and puts patients at unnecessary risk of fracture. Medical News Today 2007 Oct 23 [online]. Available from URL: http://www.medicalnewstoday.com/articles/86327.php [Accessed 2011 Jun 10] Appeal takes place against NICE osteoporosis decision which restricts access to effective medicines and puts patients at unnecessary risk of fracture. Medical News Today 2007 Oct 23 [online]. Available from URL: http://​www.​medicalnewstoday​.​com/​articles/​86327.​php [Accessed 2011 Jun 10]
209.
go back to reference National Institute for Health and Clinical Excellence. Background briefing: outcome of judicial review. London: NICE, 2007 [online]. Available from URL: http://www. nice.org.uk/nicemedia/live/11600/36563/36563.pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Background briefing: outcome of judicial review. London: NICE, 2007 [online]. Available from URL: http://​www.​ nice.org.uk/nicemedia/live/11600/36563/36563.pdf [Accessed 2011 Jun 10]
211.
go back to reference National Institute for Health and Clinical Excellence. Appeal from the Royal College of Psychiatrists and the British Geriatrics Society regarding the NICE final appraisal document: donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease [letter]. London: NICE, 2006 [online]. Available from URL: http://www.rcpsych.ac.uk/PDF/AlzletterNice0606. pdf [Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Appeal from the Royal College of Psychiatrists and the British Geriatrics Society regarding the NICE final appraisal document: donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease [letter]. London: NICE, 2006 [online]. Available from URL: http://​www.​rcpsych.​ac.​uk/​PDF/​AlzletterNice060​6.​ pdf [Accessed 2011 Jun 10]
212.
go back to reference National Institute for Health and Clinical Excellence. Appraisal of the use of human growth hormone for the treatment of adults with growth hormone deficiency: decision of the panel. London: NICE, 2003 [online]. Available from URL: http://www.nice.org.uk/nicemedia/ live/ 11503/37378/37378.pdf[Accessed 2011 Jun 10] National Institute for Health and Clinical Excellence. Appraisal of the use of human growth hormone for the treatment of adults with growth hormone deficiency: decision of the panel. London: NICE, 2003 [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​ live/ 11503/37378/37378.pdf[Accessed 2011 Jun 10]
Metadata
Title
Societal Values in the Allocation of Healthcare Resources
Is it All About the Health Gain?
Authors
Dr Tania Stafinski
Devidas Menon
Deborah Marshall
Timothy Caulfield
Publication date
01-12-2011
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 4/2011
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.2165/11588880-000000000-00000

Other articles of this Issue 4/2011

The Patient - Patient-Centered Outcomes Research 4/2011 Go to the issue

Acknowledgments

Acknowledgment

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.